Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Kestler

Nurse Practitioner Seaford, DE Nurse Practitioner

NPI 1255988770 CMS profile 10534849

220 Pennsylvania Ave, Seaford, DE 19973

Open in the dashboard

General payments

$5,120

151 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Kestler of Seaford, DE is reported in the CMS Open Payments database as having received $5,120 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,032 33
2024 General $1,865 49
2023 General $1,790 48
2022 General $233 10
2021 General $200 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Kestler
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melissa Kestler were reported at $1,032. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melissa Kestler Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $200 $135 $40–$426 $132
2022 $233 $152 $48–$470 $149
2023 $1,790 $166 $54–$529 $160
2024 $1,865 $173 $55–$556 $164
2025 $1,032 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,250 24 payments
  2. Axonics Modulation Technologies, Inc. $618 8 payments
  3. Janssen Biotech, Inc. $569 13 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $526 23 payments
  5. Progenics Pharmaceuticals, Inc. $389 9 payments
  6. AbbVie, Inc. $371 13 payments
  7. Merck Sharp & Dohme Corporation $216 10 payments
  8. Astellas Pharma US Inc $135 3 payments
  9. Sumitomo Pharma America, Inc. $133 6 payments
  10. Teleflex LLC $106 3 payments
  11. Other $808 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,957 138 payments
  2. Travel and Lodging $1,037 11 payments
  3. Education $127 2 payments
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,192 23 payments
  2. Axonics $618 8 payments
  3. Xofigo $526 23 payments
  4. Nubeqa $526 23 payments
  5. ERLEADA $499 12 payments
  6. PYLARIFY $389 9 payments
  7. KEYTRUDA $216 10 payments
  8. BOTOX Botox Therapeutic $170 8 payments
  9. BOTOX Urology $125 1 payment
  10. GEMTESA $98 4 payments
  11. Other $1,627 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,159

Median for Nurse Practitioner: 389

Drug cost

$128,314

Median for Nurse Practitioner: $21,885

Branded share of claims

34.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 98 $79,124
Myrbetriq Mirabegron Brand 35 $27,354
Estradiol Generic 102 $7,910
Tamsulosin Hcl Generic 347 $5,097
Oxybutynin Chloride Er Oxybutynin Chloride Brand 135 $3,311
Potassium Citrate Er Potassium Citrate Brand 16 $1,239
Finasteride Generic 60 $1,133
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 22 $733
Ciprofloxacin Hcl Generic 111 $585
Alfuzosin Hcl Er Alfuzosin Hcl Brand 16 $304

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$172,999

Of which drugs: $6,057

Medicare patients

995

Average age 75

Services billed

6,161

340 women, 655 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 43%
Diabetes 39%
Ischemic heart disease 36%
Atrial fibrillation 26%
Cancer 26%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 19 1,550 $3,432

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $300
$300 — —
BOTOX
  • AbbVie, Inc. $189
$189 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $122
$122 — —
Xofigo
  • Bayer HealthCare Pharmaceuticals Inc. $122
$122 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record